New method at the Danish Medicines Council gives Merck hope of a Danish breakthrough for its sclerosis treatment
German pharmaceutical company Merck has high hopes that a new method of evaluating treatments at the Danish Medicines Council, as well as new data, will pave the way for wider usage of sclerosis drug Mavenclad.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT
A completely new approach to evaluating the effect of treatments, as well as new data on side effects, may be the key that unlocks the Danish multiple sclerosis market for German pharmaceutical company Merck's big growth hope, Mavenclad.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
